Nitrosamine impurities are an important quality and patient-safety concern in pharmaceutical manufacturing because certain nitrosamines may pose a carcinogenic risk. Their potential presence in active pharmaceutical ingredients (APIs) and finished medicines requires a scientifically justified approach to risk assessment, testing, and control.
For pharmaceutical manufacturers and API suppliers, a nitrosamine risk assessment should do more than state that no risk has been identified. It should demonstrate that relevant materials, manufacturing processes, potential contamination routes, and available scientific evidence have been evaluated systematically.
During an audit, the objective is to determine whether the organization has identified relevant risks, justified its conclusions, and established appropriate controls.
1. A Clear and Scientifically Justified Risk Assessment
Auditors examine whether the risk assessment is documented, product-specific where appropriate, and supported by scientific reasoning.
The assessment should consider relevant factors such as:
- API and product chemistry
- Starting materials, intermediates, and raw materials
- Use of nitrites, amines, and other potentially relevant reagents
- Manufacturing process conditions and reaction pathways
- Recovered solvents, recycled materials, and shared equipment, where relevant
- Potential cross-contamination and other contamination routes
- Packaging, storage, and other relevant lifecycle considerations
The assessment should explain why a risk is considered present, absent, or requiring further investigation.
2. Manufacturing Processes and Potential Sources
Auditors review whether the organization understands how nitrosamine impurities could potentially form or enter the product.
This may include examining manufacturing steps, raw-material specifications, supplier information, process changes, and the suitability of existing controls.
For API suppliers, particular attention may be given to the relationship between process chemistry, material quality, and potential impurity formation.
A generic assessment that does not adequately consider the specific process may not provide sufficient justification for the conclusions reached.
3. Supporting Data and Analytical Testing
Where a potential risk has been identified, auditors examine whether the supporting data and testing strategy are appropriate.
Relevant evidence may include:
- Scientific assessments and documented assumptions
- Analytical method suitability and validation, as applicable
- Method sensitivity in relation to the relevant limit
- Test results and associated laboratory records
- Justification for the selected testing approach
- Evaluation of unexpected or atypical results
Testing should be scientifically justified and appropriate to the impurity and product under evaluation. A statement that testing was completed is not sufficient without evidence that the method and results support the intended conclusion.
4. Control Strategies and Risk Mitigation
Where a risk is identified, auditors assess whether appropriate measures have been established to prevent or reduce the potential presence of nitrosamines.
Depending on the risk, controls may include:
- Changes to raw-material or supplier controls
- Process adjustments or process controls
- Appropriate analytical testing
- Prevention of cross-contamination
- Supplier communication and quality agreements
- Defined acceptance criteria and escalation procedures
- Documented corrective and preventive actions (CAPA)
The control strategy should be proportionate to the identified risk and supported by evidence.
5. Change Control and Ongoing Risk Management
Nitrosamine risk assessments should be reviewed when relevant changes or new information could affect the original conclusions.
Auditors may examine how the organization evaluates changes to manufacturing processes, starting materials, suppliers, equipment, and other relevant conditions. They may also review how new scientific information, analytical findings, or regulatory updates are incorporated into the quality system.
A previously acceptable assessment may require reassessment if the underlying process or available evidence changes.
6. Common Audit Concerns
Potential concerns include:
- Risk assessments that lack product- or process-specific justification
- Important raw materials or manufacturing steps not considered
- Conclusions unsupported by adequate scientific evidence
- Analytical methods that are not suitable for their intended purpose
- Unresolved findings without appropriate investigation or action
- Inadequate documentation of decisions and assumptions
- No defined process for reviewing assessments after relevant changes
These issues do not automatically establish non-compliance in every case, but they may indicate that further evaluation is necessary.
Conclusion
A robust nitrosamine risk assessment should demonstrate a clear understanding of potential impurity sources, a scientifically justified evaluation, appropriate testing where needed, and effective risk controls.
For pharmaceutical organizations, the objective is to maintain a documented, evidence-based approach that protects product quality and supports ongoing regulatory compliance.
PharmaTrak's independent GxP audits can help organizations evaluate the adequacy of documented risk assessments, review supporting evidence, and identify gaps in supplier quality and compliance controls.
Regulatory note: This article provides general educational information and does not replace product-specific scientific evaluation or applicable regulatory requirements. Nitrosamine expectations should be checked against current guidance from the relevant authorities, including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)*.



